Another player in BC etiopathogenesis is miR-106a, which promotes cancer progression through the downregulation of RAF-1 [69], P53, BAX, and RUNX3 and the upregulation of Bcl-2 and ABCG2; it also confers cisplatin resistance upon its upregulation [70,71]. The gene discussed is TP53; the disease is breast cancer.